Literature DB >> 8382646

Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy.

H Hagiwara1, N Hayashi, E Mita, T Takehara, A Kasahara, H Fusamoto, T Kamada.   

Abstract

BACKGROUND: Interferon alfa is effective for controlling disease activity in chronic hepatitis C. However, many responders suffer relapse after cessation of therapy. In the present study, the serum concentration of hepatitis C virus RNA was correlated with a sustained response to interferon therapy.
METHODS: Fifty-three patients with chronic hepatitis C received a 26-week course of interferon alfa. Hepatitis C virus RNA was quantitated in serum at the beginning and end of treatment using a competitive assay that combined reverse transcription and polymerase chain reaction.
RESULTS: In long-term responders, whose alanine aminotransferase levels remained within the normal range during the 24 weeks after therapy, the titer of viral RNA (logarithmic transformed copy numbers per milliliter of serum) before therapy (7.1 +/- 1.2) was significantly lower (P < 0.001) than that of short-term responders (8.3 +/- 0.5) who had a relapse within the 24 weeks after therapy and nonresponders (8.1 +/- 0.4). Multivariate multiple logistic regression showed that the titer of viral RNA before therapy was the strongest independent predictor of a sustained response to interferon-alfa therapy (P = 0.002).
CONCLUSIONS: The titer of hepatitis C virus RNA is the most important factor influencing the sustained response to interferon treatment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8382646     DOI: 10.1016/0016-5085(93)91025-d

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  49 in total

1.  Clinical guidelines on the management of hepatitis C.

Authors:  J C Booth; J O'Grady; J Neuberger
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

Review 2.  Hepatitis C virus infection in the elderly. Epidemiology, prophylaxis and optimal treatment.

Authors:  J Hayashi; S Kashiwagi
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

3.  Relationship between serum HCV markers and response to interferon therapy in chronic hepatitis C. Evaluation of HCV genotypes during and after long-term follow-up.

Authors:  G Diodati; P Bonetti; A Tagger; C Casarin; F Noventa; M Ribero; M Fasola; A Ruol; G Realdi
Journal:  Dig Dis Sci       Date:  1994-11       Impact factor: 3.199

Review 4.  Hepatitis C: diagnosis and treatment.

Authors:  I Scotiniotis; C A Brass; P F Malet
Journal:  J Gen Intern Med       Date:  1995-05       Impact factor: 5.128

5.  Comparison of two quantitative hepatitis C virus reverse transcriptase PCR assays.

Authors:  W K Roth; J H Lee; B Rüster; S Zeuzem
Journal:  J Clin Microbiol       Date:  1996-02       Impact factor: 5.948

6.  Predictors of response to interferon therapy.

Authors:  G Saracco; M Rizzetto
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

7.  Quantitative detection of hepatitis C virus RNA by light cycler PCR and comparison with two different PCR assays.

Authors:  M Schröter; B Zöllner; P Schäfer; R Laufs; H H Feucht
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

8.  Clinical characterization of a competitive PCR assay for quantitative testing of hepatitis C virus.

Authors:  E P Miskovsky; A V Carrella; K Gutekunst; C A Sun; T C Quinn; D L Thomas
Journal:  J Clin Microbiol       Date:  1996-08       Impact factor: 5.948

9.  Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy.

Authors:  Pascal Veillon; Christopher Payan; Gastón Picchio; Michèle Maniez-Montreuil; Philippe Guntz; Françoise Lunel
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

10.  Efficacy of combination therapy with interferon and azidothymidine in chronic type C hepatitis: a pilot study.

Authors:  M Tsutsumi; A Takada; M Sawada
Journal:  J Gastroenterol       Date:  1995-08       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.